-- Amgen Says Xgeva Phase 3 Drug Trial Shows Improved Survival by 4.2 Months
-- B y   P e t e r   J .   B r e n n a n
-- 2010-12-13T22:57:20Z
-- http://www.bloomberg.com/news/2010-12-13/amgen-says-xgeva-phase-3-drug-trial-shows-improved-survival-by-4-2-months.html
Amgen Inc. said its top-line results
from a Phase 3 trial evaluating Xgeva demonstrated significantly
improved median bone metastasis-free survival by 4.2 months
compared to a placebo.  To contact the editor responsible for this story:
Peter J. Brennan at 
 pbrennan3@bloomberg.net  